Abstract Title:

Antibodies Against Deamidated Gliadin Peptides in Early-stage Celiac Disease.

Abstract Source:

J Clin Gastroenterol. 2010 Nov 8. Epub 2010 Nov 8. PMID: 21063208

Abstract Author(s):

Kalle Kurppa, Katri Lindfors, Pekka Collin, Päivi Saavalainen, Jukka Partanen, Katri Haimila, Heini Huhtala, Kaija Laurila, Markku Mäki, Katri Kaukinen

Article Affiliation:

*Pediatric Research Centre, University of Tampere and Tampere University Hospital†Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and Medical School ∥Tampere School of Public Health, University of Tampere, Tampere ‡Department of Medical Genetics, Haartman Institute, and Research Program for Molecular Medicine, University of Helsinki§Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland.


BACKGROUND AND GOALS: The widely used serum endomysial (EmA) and transglutaminase 2 (TG2-ab) antibodies predict forthcoming villous damage and celiac disease when the small-bowel mucosa structure is still normal. However, these autoantibodies may remain negative in this early stage of the disease. We hypothesized that the antibodies against deamidated gliadin peptides (DGP-AGA) might appear before the other antibodies and would thus be useful in the diagnosis and follow-up of patients with early-stage celiac disease. STUDY: Serum DGP-AGA, TG2-ab, and EmA were measured at baseline and after 1 year on a gluten-free diet in 42 adults proven to have early-stage celiac disease despite normal small-bowel mucosal morphology (Marsh I-II), and in 20 celiac subjects evincing villous atrophy (Marsh III). Thirty-nine subjects with no signs of celiac disease served as nonceliac controls. RESULTS: Sensitivity to detect early-stage celiac disease was 79% for DGP-AGA, 64% for TG2-ab, and 81% for EmA. Specificities were 95%, 100%, and 100%, respectively. The corresponding efficiencies of the tests were 89% for DGP-AGA, 81% for TG2-ab, and 91% for EmA. All 3 antibodies were significantly decreased on a gluten-free diet. CONCLUSIONS: This study showed that the sensitivity of DGP-AGA was superior to TG2-ab and comparable to EmA in celiac patients having early-stage celiac disease with normal villous morphology. On the basis of these results, DGP-AGA would seem to offer a promising new method for case-finding and follow-up in this entity.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.